Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol

Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol

Introduction A new concept of ‘NeoRAS wild-type (WT)’, which means conversion of RAS status from RAS mutant to RAS WT after treatment, has been reported. Previous observational and proof-of-concept studies have demonstrated the efficacy of epidermal growth factor receptor inhibitors in patients with...

Full description

Bibliographic Details
Main Authors: Atsuo Takashima, Ken Kato, Eiji Shinozaki, Kensei Yamaguchi, Takeru Wakatsuki, Hiroki Osumi, Naoki Ishizuka, Kota Ouchi, Yosuke Kumekawa, Daisuke Nakano, Manabu Shiozawa, Tadamichi Denda, Ryoichi Sawada, Boku Narikazu
Format: Article
Language:English
Published: BMJ Publishing Group 2022-09-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/9/e063071.full

Internet

https://bmjopen.bmj.com/content/12/9/e063071.full

Similar Items